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Abstract 
 
Background: In EchoCRT, a randomized controlled trial evaluating the effect of CRT in 
patients with a QRS duration <130 msec and echocardiographic evidence of left ventricular 
dyssynchrony, the primary outcome (death from any cause or first hospitalization for 
worsening heart failure) occurred more frequently in the CRT-ON as compared with the 
control group. In this pre-specified subgroup analysis we evaluated the effect of gender on 
clinical outcome in EchoCRT. 
Methods and Results: In EchoCRT, 585 (72%) of included patients were men. At baseline, 
male patients had a higher incidence of ischemic cardiomyopathy and longer QRS duration. 
On uni- and multivariable analysis, no significant interaction was observed regarding gender 
for the primary or any of the secondary endpoints. Numerically, a higher all-cause mortality 
was observed in male patients randomized to CRT-ON vs. CRT-OFF on univariable analysis 
(HR 1.83, 95% CI 1.08 - 3.12); however, no statistically significant interaction compared to 
females randomized to CRT-ON vs. CRT-OFF was noted (HR 0.99, p interaction = 0.56). 
There was no difference in the primary safety endpoint of system-related complications, 
including CRT system- and implantation-related events. 
Conclusions: The largest hazard for all-cause mortality in EchoCRT was observed in men 
randomized to CRT-ON; the comparison with women did not reach statistical significance, 
which may be due to the premature termination of the trial and the limited data. These results 
suggest that male gender may be a risk factor for harm by CRT in patients with narrow QRS 
width, an observation which deserves further investigation. 
Clinical Trial Registration Information: NCT00683696 (https://clinicaltrials.gov)  
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Introduction 
 
 Cardiac resynchronization therapy (CRT) has been demonstrated to reduce morbidity 
and mortality in numerous large clinical trials, and has become an integral part of 
contemporary heart failure therapy. 1-3 The inclusion criteria of these trials form the basis of 
current guidelines, recommending CRT for patients with a severely reduced left ventricular 
ejection fraction (EF ≤ 35%), symptomatic chronic heart failure (CHF), and a QRS complex ≥ 
120 msec.4 Since the majority of CHF patients present with a narrow QRS complex,5 the 
EchoCRT trial was designed to investigate the effect of CRT in patients with a QRS duration 
≤ 130 msec together with echocardiographic evidence of left ventricular dyssynchrony.6 The 
trial was terminated early due to futility, but also indicated an increased risk for all-cause 
mortality of 81% with CRT in this patient population. The gender distribution, as well as the 
reason for the overall increase in mortality observed in Echo CRT is presently still unclear. 
 Gender specific results of CRT have been suggested by some, but not all, prior studies. 
CARE-HF or REVERSE were unable to find a gender-by-treatment interaction. In contrast, in 
MADIT-CRT, women experienced a 79% reduction in the primary endpoint (death or heart 
failure) as compared to only 28% in men. More recently, pronounced female advantage for 
CRT effect was seen at shorter (120-150 msec) QRS durations.7, 8 
 Whether the lack of benefit for CRT shown in EchoCRT pertains to all patients, or 
whether male or female patients with a narrow QRS complex and echocardiographic signs of 
dyssynchrony may derive a benefit (or particularly pronounced harm) from CRT is presently 
unclear. The current pre-specified subgroup analysis was therefore performed to assess the 
effect of gender on clinical outcome in EchoCRT. 
 
 
Methods 
 
Study design and conduct 
 The EchoCRT study was an investigator-initiated, international, multicenter, 
randomized clinical trial. The outcome results of the main trial, as well as the methodology 
have previously been reported.6 In brief, the trial (sponsored by Biotronik) was designed by 
the executive committee with support for echocardiographic training and software provided 
by GE Healthcare. All study results were independently analyzed at the Robertson Centre for 
Biostatistics at the University of Glasgow. Patients were eligible if they had New York Heart 
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Association (NYHA) class III or IV heart failure; a left ventricular EF of 35% or less; a 
standard indication for an implantable cardioverter–defibrillator (ICD); optimized medical 
heart failure therapy; a QRS duration of less than 130 msec; a left ventricular end-diastolic 
diameter (LVEDD) of 55 mm or more; and echocardiographic evidence of left ventricular 
dyssynchrony as previously defined.6 After implantation of a Biotronik Lumax HF-T CRT-D 
system, patients were randomly assigned in a 1:1 ratio to have CRT capability turned on (the 
CRT group) or to have CRT capability turned off (the control group). Device-implanting 
physicians were aware of the study-group assignments, but the patients, heart-failure 
physicians, and study personnel completing the follow-up assessments were unaware of the 
group assignments. The trial protocol was approved by the institutional review board at each 
participating center, and all subjects provided written informed consent. 
 
Endpoints 
 The primary efficacy outcome was the combination of death from any cause or first 
hospitalization for worsening heart failure.6 The pre-specified secondary outcomes included 
all hospitalizations for worsening heart failure throughout the study; all-cause mortality, 
cardiovascular mortality; heart failure mortality and cardiovascular hospitalization.6 The 
primary safety outcome was freedom from CRT-D related complications at 6 months in the 
implanted population. Complications were defined as adverse events that require additional 
invasive intervention to resolve, related to the implanted CRT system including the device 
and leads. In addition, system related complications during the whole trial were analyzed by 
treatment group.  
 
Statistical analysis  
All analyses were performed according to the intention-to-treat principle. Baseline 
characteristics were compared with the use of two-sample t-tests and chi-square (or Fisher’s 
exact) tests for continuous and categorical variables, respectively.  
Hazard ratios (HRs) for CRT-ON and CRT-OFF with 95% confidence intervals were 
calculated with the Cox proportional hazards models for male vs. female patients including 
the stratification factor of country in the model. Additionally, a multivariable Cox 
proportional hazards model was performed to account for differences across randomized 
treatment groups in baseline characteristics between males and females (QRS width, walking 
distance, QOL score, sitting DBP, ischemic cardiomyopathy, history of myocardial infarction, 
history of CABG, LVEDD, diuretic agent use).  Interactions between males and females and 
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treatment (CRT=ON and CRT=OFF) were tested for in Cox models that included gender and 
treatment main effects and interaction terms.  Time to event curves were estimated with the 
use of the Kaplan-Meier method. All tests were two-sided with a p value <0.05 considered to 
be significant. Analyses were performed using SAS for Windows version 9.2. 
 
 
Results 
 
Baseline characteristics 
 Metrics at trial entry are summarized in table 1. Out of 809 randomized patients, 224 
(27.7%) were females. Male patients had longer QRS complex duration, longer walking 
distance, slightly higher diastolic blood pressure, larger LV diameters, and more frequently 
had ischemic cardiomyopathy or related interventions. In contrast, women had higher quality 
of life scores and higher use of diuretics. Other baseline parameters were comparable amongst 
the two groups. 
 
Efficacy of CRT in male vs. female patients 
 There was no difference for male vs. female patients regarding the overall results of 
the trial, both unadjusted (Fig. 1, 2) and after multivariable adjustment for differences in 
baseline characteristics as outlined above (i.e. QRS width, walking distance, QOL score, 
sitting DBP, ischemic cardiomyopathy, history of myocardial infarction, history of CABG, 
LVEDD, diuretic agent use; Fig. 3). Numerically, however, both the increased hazard of CRT 
for the primary endpoint, as well as particularly for the mortality endpoints appeared to be 
driven mainly by an increased hazard in male patients. Most pronounced, cardiovascular 
mortality was increased 2.4-fold in male patients (HR 2.43 (95% CI 1.27 - 4.63), p=0.007 vs. 
HR 0.97 (95% CI 0.24 - 3.93), p=0.97 for the females), albeit with a non-significant 
interaction p-value. These observations were paralleled in the Kaplan Meier analyses as well 
as in the multivariable adjusted model (again, however, without significant interaction).  
 
Device related complications in male vs. female patients 
The primary safety endpoint (freedom from device-related complications at 6 months) in the 
implanted population (237 females and 618 males) is presented in table 2. There were no 
differences in the primary safety endpoint, including CRT system- and implantation-related 
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events. Device-related complications occurring during the whole trial in male and female 
patients are summarized in table 3. The rate of ICD lead related complications was 
numerically higher in women in the CRT-ON group, which was counterbalanced by a 
numerically lower rate of ICD lead complications in the CRT-OFF group in women (both as 
compared to men). Overall, the difference between ICD lead related complications was 
similar and did not reach statistical significance.  
 
 
Discussion 
 
In the current pre-specified subgroup analysis, a trend indicating a worse outcome for males 
compared to females can be observed. Indeed, on Kaplan-Meier analysis, the event curve for 
CRT-ON in women is almost a perfect match to that of CRT-OFF in women as well as in 
men, possibly indicating a balanced effect (i.e. harm in some neutralized by benefit in others).  
In contrast, male patients appear to be the main driver of worse outcomes of CRT-ON for the 
entire EchoCRT cohort. The lack of statistical significance may be due to the fact that the trial 
was prematurely terminated, resulting in a lack of statistical power both for the primary as for 
the secondary endpoints, which becomes even more relevant in subgroup analysis. It is 
tempting to speculate that had the trial been terminated as planned, a statistically significant 
interaction may have been observed. 
 Our results indicating potential gender-specific differences in CRT effect are 
consistent with several other large outcome studies, extending those observations to the 
narrow QRS range studied here. In the early Multicenter InSync Randomized Clinical 
Evaluation (MIRACLE) Study, women, but not men, receiving CRT had a longer time to first 
hospitalization for CHF as well as time to first CHF hospitalization or death.9 In MADIT-
CRT, female patients randomized to CRT treatment had a 69% relative risk reduction to 
experience the primary endpoint of death or heart failure vs. ICD as compared to men, who 
only had 28% relative risk reduction (p interaction < 0.001). This effect was driven both by a 
significant reduction in heart failure hospitalization (70% vs. 35% risk reduction) and a 
significant reduction in all-cause mortality. Indeed, a reduction in all-cause mortality was 
primarily evident in women (HR 028, 95% CI 0.10-0.79), but not in men (HR 1.05, 95% CI 
0.70-1.57; p interaction = 0.03). A similar trend was also observed in the Resynchronization–
Defibrillation for Ambulatory Heart Failure Trial (RAFT), the other large study investigating 
CRT in oligosymptomatic patients (p interaction 0.09).10 Finally, a large single center CRT 
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registry found a significant 56% lower all-cause mortality in women compared to men on 
multivariable analysis.11 When considered against QRS duration, female advantage (relative 
to male patients) was most pronounced at shorter (<150 msec) QRS durations.7 In contrast, 
some other studies have failed to demonstrate a significant difference between men and 
women, including CARE-HF.1 Similarly in the COMPANION trial, no interaction by gender 
was observed although women did have a lower hazard for sudden cardiac death or 
appropriate shocks.3, 12  
 The reason for these differences is just as elusive as the mechanism underlying a 
potentially more pronounced benefit of CRT in women. Several explanations have been 
brought forward, including a higher proportion of ischemic cardiomyopathies as well as larger 
LV diameters in males. Indeed, the latter may play an important role, consistent with a “point 
of no return” in the natural course of CHF after which reverse LV remodeling – and, as a 
consequence, response to CRT – becomes less likely.13-15 Another hypothesis is related to the 
difference in QRS duration between men and women. Indeed, in healthy women (as well as in 
EchoCRT), the QRS duration is on average 4-10msec shorter than that in male patients.16, 17 
As a result, male patients with a prolonged QRS complex may have relatively less electrical 
dyssynchrony and intracardiac conduction disturbance for any given absolute QRS duration 
as compared to women, which may explain the more favorable outcome of CRT in females. 
Possibly, in shorter QRS ranges as examined here, there is little if any dyssynchrony among 
males.18 For these patients, ventricular stimulation itself may be associated with a worse 
outcome, similar to the development of pacemaker-mediated cardiomyopathy.19 Indeed, 
separation of the KM curve for CRT-ON in males mostly occurs 1.5 – 2 years after 
implantation, which may indicate a detrimental effect of ventricular pacing on LV function in 
patients without relevant dyssynchrony, comparable to that of a pacer-mediated 
cardiomyopathy. In contrast, this phenomenon appears less pronounced in longer QRS 
durations (i.e., >150msec), after which the relative benefit of male and female patients 
appears more similar.7, 8  In our subgroup analysis, male patients had larger LV diameters, 
longer QRS duration, and more frequently had ischemic cardiomyopathy, prior myocardial 
infarction and prior CABG. Although patients with prior myocardial infarction are generally 
less likely to respond to CRT20 or become super-responders,21 ischemic cardiomyopathy itself 
has not consistently been associated with a worse outcome in terms of hard endpoints in any 
of the major randomized clinical trials.1, 22, 23 The gender pattern observed on univariable 
analysis was still evident after multivariable adjustment, indicating an effect independent of, 
or at least in addition to those parameters.  
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 In spite of the increasing evidence of a similar, if not more pronounced benefit of CRT 
in women, CRT remains largely underused in female compared to male patients. In absolute 
terms, women constitute a large proportion of the CHF population.11, 24 This is in sharp 
contrast to the proportion of women included in CRT trials (including EchoCRT), ranging 
from 17.2% (RAFT) to 32% (COMPANION).2, 3, 6 Similarly, CRT remains underused in daily 
clinical practice, as shown by only 27% females implanted in the Euro CRT survey.25 Our 
current analysis cannot readily supply an answer to this phenomenon. A larger concern for 
complications after device implantation, both from female patients as well as from the 
referring / implanting physician has been suggested, likely due to smaller vessel diameter and 
body size.11, 26 In our analysis, the system- / implantation-related complication rate was 
similar for men as compared to women indicating that this factor per se should not discourage 
CRT implants in women.  
 
 
Limitations 
 
Although prespecified, this subgroup analysis of EchoCRT should by definition be interpreted 
as hypothesis generating, especially since the trial did not meet its primary endpoint. Gender 
was not a stratification factor at trial entry leaving the possibility of unmeasured residual 
confounding. Moreover, the trial was prematurely terminated, further reducing the statistical 
power of any subgroup analysis. Although the proportion of women included in Echo CRT is 
in line with other contemporary CRT trials, inclusion of a higher number of women may have 
increased statistical power for this subgroup analysis.  
 
 
 
Conclusion 
 
In the present pre-specified subgroup analysis of EchoCRT, a trend indicating a worse 
outcome for males compared to females can be observed with CRT-ON vs. CRT-OFF. This 
did not reach statistical significance, likely due to lack of power resulting from the premature 
termination of the trial. These data extend findings from previous large randomized trials and 
support the use of CRT in female patients if indicated according to current guidelines. 
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Importantly, these data serve as a reminder to use caution with CRT implantation in men with 
a narrow QRS complex irrespective of the presence of mechanical dyssynchrony. 
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Tables 
 
 
Tab. 1: Baseline characteristics 
For categorical variables number and percentage are reported; for continuous variables mean 
and standard deviation are reported (except for BNP and NT-proBNP where median and 
inter-quartile range are presented). * p-value not reported due to small numbers.  
 
Variable Females Males P-value 
Age (years) 57.5 (13.62) 58.2 (12.38) 0.482 
QRS width (msec; site) 102.4 (12.89) 106.3 (12.70) <0.001 
QRS width (msec; core) 102.3 (13.35) 107.1 (12.01) <0.001 
Walking distance (m) 286.7 (120.64) 340.4 (116.84) <0.001 
Quality of life score 54.4 (24.15) 50.0 (24.21) 0.021 
NYHA Classification 
I 0 (0.00%) 5 (0.85%) * 
II 3 (1.34%) 16 (2.74%)   
III 213 (95.09%) 546 (93.33%)   
IV 8 (3.57%) 18 (3.08%)   
BNP (pg/ml) 225.0 (102.00, 471.00) 251.0 (75.00, 515.00) 0.927 
NT-proBNP (pg/ml) 1275.0 (610.00, 2124.0) 1095.5 (449.50, 2408.5) 0.604 
Sitting SBP (mmHg) 117.6 (18.11) 119.3 (19.87) 0.271 
Sitting DBP (mmHg) 71.4 (11.18) 73.3 (12.20) 0.039 
BMI (kg/m2) 31.7 (14.80) 30.5 (10.98) 0.212 
Ischemic cardiomyopathy 88 (39.29%) 344 (58.90%) <0.001 
MI >  3 months ago 66 (29.46%) 256 (43.76%) <0.001 
PCI > 3 months ago 70 (31.25%) 218 (37.26%) 0.110 
CABG > 3 months ago 23 (10.27%) 128 (21.88%) <0.001 
Hypertension 146 (66.06%) 387 (66.61%) 0.884 
Congenital heart disease 2 (0.92%) 14 (2.42%) 0.259 
Prior ischemic stroke or TIA 27 (12.22%) 69 (11.86%) 0.888 
Diabetes mellitus 95 (42.79%) 225 (38.53%) 0.269 
Chronic lung disease 40 (18.02%) 109 (18.79%) 0.801 
Chronic kidney disease 22 (9.95%) 86 (14.78%) 0.074 
LVEF Biplane (%) 27.2 (5.39) 26.9 (5.63) 0.477 
LV end diastolic dimeter (mm) 64.1 (6.84) 67.3 (7.62) <0.001 
Qualified by TDI and/or radial dyssynchrony 
Tissue Doppler imaging only 50 (22.32%) 152 (26.03%) 0.050 
Radial strain only 42 (18.75%) 143 (24.49%)   
TDI and radial strain 132 (58.93%) 289 (49.49%)   
Medication at study entry     
ACE inhibitor or ARB 212 (94.64%) 555 (94.87%) 0.896 
Aldosterone antagonist 130 (58.04%) 355 (60.68%) 0.492 
Beta-blocker 216 (96.43%) 566 (96.75%) 0.828 
Diuretic agent 206 (91.96%) 492 (84.10%) 0.004 
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Tab. 2: Primary Safety Endpoint in female and male patients (complication-free rate 
within 6 months of implantation) 
 
  Female patients (%)  
Complication-Free  
(n total =237) 
Male patients (%) 
Complication-Free  
(n total =618) 
p int 
CRT-D system 216 (91.14%) 569 (92.07%) 0.66 
Implant procedure 232 (97.89%) 605 (97.90%) 1 
Other 236 (99.58%) 617 (99.84%) 0.50 
Any of the above 210 (88.61%) 556 (89.97%) 0.56 
 
 
 
 
Tab. 3: CRT system related serious adverse events during the whole trial 
N = Number of events; N pts = Number of patients with events 
 
  Female patients Male patients  p int 
  CRT=ON    
(N= 110) 
CRT=OFF  
(N= 114) 
CRT=ON 
(N=294) 
CRT=OFF 
(N=291) 
  
  N N pts. N N pts. N N pts. N N pts. 
 
CRT system related 26 19 (17.27%) 7 7 (6.14%) 48 36 (12.24%) 25 22 (7.56%) 0.25 
     ICD lead 10 9 (8.18%) 2 2 (1.75%) 16 14 (4.76%) 11 11 (3.78%) 0.13 
     RA pacing lead 7 5 (4.55%) 1 1 (0.88%) 14 13 (4.42%) 4 4 (1.37%) 0.70 
     LV pacing lead 7 6 (5.45%) 2 2 (1.75%) 14 12 (4.08%) 2 2 (0.69%) 0.57 
Implantation related 6 6 (5.45%) 3 3 (2.63%) 13 11 (3.74%) 15 13 (4.47%) 0.26 
 
 
  
19 / 19 
Figure Legends 
 
 
Fig 1.: Kaplan–Meier Estimates for Primary-Outcome Events, stratified by gender. 
Kaplan–Meier curves for the primary composite efficacy outcome of death from any cause or 
hospitalization for heart failure, as well as the secondary endpoints  in patients randomized to 
CRT-ON and CRT-OFF , stratified by gender. 
 
Fig 2: Effect of CRT in female (upper, black) and male (lower, red) patients.  
Hazard ratio (HR; 95% confidence interval (CI) ) adjusted for country and p-value from Wald 
test are presented.  
 
Fig. 3: Effect of CRT in female (upper, black) and male (lower, red) patients after 
multivariable adjustment 
Hazard ratio (95% confidence interval) adjusted for country, QRS width, walking distance, 
QOL score, sitting DBP, ischemic cardiomyopathy, history of myocardial infarction, history 
of CABG, LVEDD, diuretic agent use (p-value from Wald test.) 
 
 
Fig 1.: Kaplan–Meier Estimates for Primary-Outcome Events, stratified by gender. 
Kaplan–Meier curves for the primary composite efficacy outcome of death from any cause or 
hospitalization for heart failure, as well as the secondary endpoints  in patients randomized to 
CRT-ON and CRT-OFF , stratified by gender. 
  
All-Cause Mortality
CRT=OFF, FEMALE 114 86 67 49 32 19 12 2
CRT=ON, FEMALE 110 73 56 38 27 16 9 5
CRT=OFF, MALE 291 216 169 117 87 52 32 13
CRT=ON, MALE 294 224 167 117 76 49 33 14
No. At risk
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Fig 2: Effect of CRT in female (upper, black) and male (lower, red) patients.  
Hazard ratio (HR; 95% confidence interval (CI) ) adjusted for country and p-value from Wald test are presented.  
 
 
  
Endpoint CRT=OFF CRT=ON Adjusted HR (95% CI) P-value p int.
Death or WHF 
hospitalisation
34 (29.82%) 30 (27.27%) 0.93 (0.56 - 1.56) 0.788 0.428
68 (23.37%) 86 (29.25%) 1.31 (0.95 - 1.80) 0.097
WHF hospitalisation
33 (28.95%) 29 (26.36%) 0.93 (0.55 - 1.57) 0.793 0.474
57 (19.59%) 70 (23.81%) 1.28 (0.90 - 1.82) 0.169
All cause mortality
5 (4.39%) 5 (4.55%) 0.99 (0.28 - 3.45) 0.981 0.560
21 (7.22%) 40 (13.61%) 1.83 (1.08 - 3.12) 0.026
Cardiovascular mortality
4 (3.51%) 4 (3.64%) 0.97 (0.24 - 3.93) 0.966 0.371
13 (4.47%) 33 (11.22%) 2.43 (1.27 - 4.63) 0.007
Heart failure mortality
3 (2.63%) 2 (1.82%) 0.58 (0.10 - 3.51) 0.558 0.322
7 (2.41%) 15 (5.10%) 2.07 (0.84 - 5.11) 0.115
Cardiovascular 
hospitalisation
45 (39.47%) 37 (33.64%) 0.82 (0.52 - 1.29) 0.391 0.249
92 (31.62%) 110 (37.41%) 1.22 (0.92 - 1.61) 0.171
0.1 0.2 0.5 1 2 5 10
Female
Male
4 / 4 
Fig. 3: Effect of CRT in female (upper, black) and male (lower, red) patients after multivariable adjustment 
Hazard ratio (95% confidence interval) adjusted for country, QRS width, walking distance, QOL score, sitting DBP, ischemic 
cardiomyopathy, history of myocardial infarction, history of CABG, LVEDD, diuretic agent use (p-value from Wald test.) 
 
 
 
Endpoint CRT=OFF CRT=ON Adjusted HR (95% CI) p value p int.
Death or WHF hospitalisation
34 (29.82%) 30 (27.27%) 0.91 (0.53 - 1.56) 0.733 0.395
68 (23.37%) 86 (29.25%) 1.37 (0.99 - 1.90) 0.058
WHF hospitalisation
33 (28.95%) 29 (26.36%) 0.92 (0.53 - 1.59) 0.759 0.49
57 (19.59%) 70 (23.81%) 1.35 (0.94 - 1.93) 0.104
Cardiovascular hospitalisation
45 (39.47%) 37 (33.64%) 0.75 (0.46 - 1.22) 0.243 0.177
92 (31.62%) 110 (37.41%) 1.21 (0.91 - 1.61) 0.189
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